FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912232363> ?p ?o ?g. }

• W2912232363 endingPage "637" @default.
• W2912232363 startingPage "632" @default.
• W2912232363 abstract "Summary Aims Irritability has been described as a frequent adverse event in patients affected by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less frequently with valproic acid (VPA). Since the questionnaire for irritability (I‐EPI) is a validated instrument to measure this psychiatric manifestation in patients affected by epilepsy, in this study we aimed at investigating the effect of PER as first add‐on therapy on I‐EPI. Moreover, we compared the effectiveness and I‐EPI scores obtained at 12‐month follow‐up visits in patients treated by PER, LEV, or VPA in order to measure irritability as a consequence of these treatments. Methods We collected data from 17 patients treated by PER, 16 patients treated by LEV, and 16 patients under VPA treatment followed for 12 months. Results We did not document significant changes of I‐EPI questionnaire between baseline and follow‐up in the PER group. As concerning the comparison of I‐EPI among PER, LEV, and VPA groups, we documented lower global scores in PER than both LEV ( P < 0.05) and VPA ( P < 0.05) groups. Moreover, patients under PER treatment showed lower scores than LEV and VPA ( P < 0.05) in I‐EPI items measuring the gentle personality, anxiety of having epileptic seizures in front of others, and irritability in thinking that they can have an epileptic seizure. Conclusions This retrospective study described a stable and possibly lower degree of irritability in patients starting PER than LEV and VPA treatments, although we documented the comparable effectiveness of PER, LEV, and VPA as first add‐on treatments in patients affected by uncontrolled epileptic seizures. However, the small sample of patients included in this study and the absence of I‐EPI scores obtained at baseline visits in LEV and VPA groups require further investigations to confirm this preliminary evidence." @default.
• W2912232363 created "2019-02-21" @default.
• W2912232363 creator A5009244024 @default.
• W2912232363 creator A5017127584 @default.
• W2912232363 creator A5039042041 @default.
• W2912232363 creator A5063327666 @default.
• W2912232363 creator A5082528797 @default.
• W2912232363 creator A5088970392 @default.
• W2912232363 creator A5089506386 @default.
• W2912232363 date "2019-01-23" @default.
• W2912232363 modified "2023-10-12" @default.
• W2912232363 title "Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid" @default.
• W2912232363 cites W1488798108 @default.
• W2912232363 cites W1862576101 @default.
• W2912232363 cites W1868997350 @default.
• W2912232363 cites W1988932597 @default.
• W2912232363 cites W2022919161 @default.
• W2912232363 cites W2026700713 @default.
• W2912232363 cites W2028221836 @default.
• W2912232363 cites W2035692551 @default.
• W2912232363 cites W2038637511 @default.
• W2912232363 cites W2046252007 @default.
• W2912232363 cites W2058945163 @default.
• W2912232363 cites W2060121528 @default.
• W2912232363 cites W2132146185 @default.
• W2912232363 cites W2138763308 @default.
• W2912232363 cites W2171969705 @default.
• W2912232363 cites W2186105609 @default.
• W2912232363 cites W2207060365 @default.
• W2912232363 cites W2220301735 @default.
• W2912232363 cites W2470130418 @default.
• W2912232363 cites W2500514079 @default.
• W2912232363 cites W2526592858 @default.
• W2912232363 cites W2531440023 @default.
• W2912232363 cites W2754524371 @default.
• W2912232363 cites W2759205442 @default.
• W2912232363 cites W2761090583 @default.
• W2912232363 cites W2792383391 @default.
• W2912232363 cites W2792950270 @default.
• W2912232363 cites W2797635914 @default.
• W2912232363 doi "https://doi.org/10.1111/cns.13098" @default.
• W2912232363 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6488879" @default.
• W2912232363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30675751" @default.
• W2912232363 hasPublicationYear "2019" @default.
• W2912232363 type Work @default.
• W2912232363 sameAs 2912232363 @default.
• W2912232363 citedByCount "8" @default.
• W2912232363 countsByYear W29122323632019 @default.
• W2912232363 countsByYear W29122323632020 @default.
• W2912232363 countsByYear W29122323632021 @default.
• W2912232363 countsByYear W29122323632023 @default.
• W2912232363 crossrefType "journal-article" @default.
• W2912232363 hasAuthorship W2912232363A5009244024 @default.
• W2912232363 hasAuthorship W2912232363A5017127584 @default.
• W2912232363 hasAuthorship W2912232363A5039042041 @default.
• W2912232363 hasAuthorship W2912232363A5063327666 @default.
• W2912232363 hasAuthorship W2912232363A5082528797 @default.
• W2912232363 hasAuthorship W2912232363A5088970392 @default.
• W2912232363 hasAuthorship W2912232363A5089506386 @default.
• W2912232363 hasBestOaLocation W29122323631 @default.
• W2912232363 hasConcept C118552586 @default.
• W2912232363 hasConcept C126322002 @default.
• W2912232363 hasConcept C15744967 @default.
• W2912232363 hasConcept C187212893 @default.
• W2912232363 hasConcept C197934379 @default.
• W2912232363 hasConcept C2777172819 @default.
• W2912232363 hasConcept C2777332695 @default.
• W2912232363 hasConcept C2778186239 @default.
• W2912232363 hasConcept C2780820931 @default.
• W2912232363 hasConcept C2780836401 @default.
• W2912232363 hasConcept C42219234 @default.
• W2912232363 hasConcept C558461103 @default.
• W2912232363 hasConcept C71924100 @default.
• W2912232363 hasConceptScore W2912232363C118552586 @default.
• W2912232363 hasConceptScore W2912232363C126322002 @default.
• W2912232363 hasConceptScore W2912232363C15744967 @default.
• W2912232363 hasConceptScore W2912232363C187212893 @default.
• W2912232363 hasConceptScore W2912232363C197934379 @default.
• W2912232363 hasConceptScore W2912232363C2777172819 @default.
• W2912232363 hasConceptScore W2912232363C2777332695 @default.
• W2912232363 hasConceptScore W2912232363C2778186239 @default.
• W2912232363 hasConceptScore W2912232363C2780820931 @default.
• W2912232363 hasConceptScore W2912232363C2780836401 @default.
• W2912232363 hasConceptScore W2912232363C42219234 @default.
• W2912232363 hasConceptScore W2912232363C558461103 @default.
• W2912232363 hasConceptScore W2912232363C71924100 @default.
• W2912232363 hasFunder F4320322148 @default.
• W2912232363 hasIssue "5" @default.
• W2912232363 hasLocation W29122323631 @default.
• W2912232363 hasLocation W29122323632 @default.
• W2912232363 hasLocation W29122323633 @default.
• W2912232363 hasLocation W29122323634 @default.
• W2912232363 hasLocation W29122323635 @default.
• W2912232363 hasOpenAccess W2912232363 @default.
• W2912232363 hasPrimaryLocation W29122323631 @default.
• W2912232363 hasRelatedWork W1967940919 @default.
• W2912232363 hasRelatedWork W2912232363 @default.
• W2912232363 hasRelatedWork W2989794697 @default.

• next